The report of these two cases provides proof of concept that the anti-PD-1 therapy-mediated modulation of the adenosine methylation level of miR-125a-5p can be analyzed by considering exomiR-125a-5p in longitudinal blood samples of lung cancer patients. This evidence concerns the gene PDCD1 and lung carcinoma.